New Oral Anticoagulants May Be Particularly Useful for Asian Stroke Patients
0
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Atrial fibrillation (AF) is an emerging epidemic in both high-income and low-income countries, mainly because of global population aging. Stroke is a major complication of AF, and AF-related ischemic stroke is more disabling and more fatal than other types of ischemic stroke. However, because of concerns about bleeding complications, particularly intracranial hemorrhage, and the limitations of a narrow therapeutic window, warfarin is underused. Four large phase III randomized controlled trials in patients with non-valvular AF (RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48) demonstrated that new oral anticoagulants (NOACs) are superior or non-inferior to warfarin as regards their efficacy in preventing ischemic stroke and systemic embolism, and superior to warfarin in terms of intracranial hemorrhage. Among AF patients receiving warfarin, Asians compared to non-Asians are at higher risk of stroke or systemic embolism and are also more prone to develop major bleeding complications, including intracranial hemorrhage. The extra benefit offered by NOACs over warfarin appears to be greater in Asians than in non-Asians. In addition, Asians are less compliant, partly because of the frequent use of herbal remedies. Therefore, NOACs compared to warfarin may be safer and more useful in Asians than in non-Asians, especially in stroke patients. Although the use of NOACs in AF patients is rapidly increasing, guidelines for the insurance reimbursement of NOACs have not been resolved, partly because of insufficient understanding of the benefit of NOACs and partly because of cost concerns. The cost-effectiveness of NOACs has been well demonstrated in the healthcare settings of developed countries, and its magnitude would vary depending on population characteristics as well as treatment cost. Therefore, academic societies and regulatory authorities should work together to formulate a scientific healthcare policy that will effectively reduce the burden of AF-related stroke in this rapidly aging society.
Abstract
Atrial fibrillation (AF) is an emerging epidemic in both high-income and low-income countries, mainly because of global population aging. Stroke is a major complication of AF, and AF-related ischemic stroke is more disabling and more fatal than other types of ischemic stroke. However, because of concerns about bleeding complications, particularly intracranial hemorrhage, and the limitations of a narrow therapeutic window, warfarin is underused. Four large phase III randomized controlled trials in patients with non-valvular AF (RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48) demonstrated that new oral anticoagulants (NOACs) are superior or non-inferior to warfarin as regards their efficacy in preventing ischemic stroke and systemic embolism, and superior to warfarin in terms of intracranial hemorrhage. Among AF patients receiving warfarin, Asians compared to non-Asians are at higher risk of stroke or systemic embolism and are also more prone to develop major bleeding complications, including intracranial hemorrhage. The extra benefit offered by NOACs over warfarin appears to be greater in Asians than in non-Asians. In addition, Asians are less compliant, partly because of the frequent use of herbal remedies. Therefore, NOACs compared to warfarin may be safer and more useful in Asians than in non-Asians, especially in stroke patients. Although the use of NOACs in AF patients is rapidly increasing, guidelines for the insurance reimbursement of NOACs have not been resolved, partly because of insufficient understanding of the benefit of NOACs and partly because of cost concerns. The cost-effectiveness of NOACs has been well demonstrated in the healthcare settings of developed countries, and its magnitude would vary depending on population characteristics as well as treatment cost. Therefore, academic societies and regulatory authorities should work together to formulate a scientific healthcare policy that will effectively reduce the burden of AF-related stroke in this rapidly aging society.
참고문헌 (46)
- Gomes T., "Persistence with therapy among patients treated with warfarin for atrial fibrillation", Arch Intern Med, 172, pp.1687~1689 (2012)
- Gallagher AM., "Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients", Thromb Haemost, 106, pp.968~977 (2011)
- Connolly SJ., "Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range", Circulation, 118, pp.2029~2037 (2008)
- Connolly SJ., "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
- Patel MR., "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
- Granger CB., "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
- Giugliano RP., "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
- Palareti G., "Bleeding complications of oral anticoagulant treatment : an inception-cohort, prospective collaborative study(ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy", Lancet, 348, pp.423~428 (1996)
- Phillips KW., "The clinical implications of new oral anticoagulants : will the potential advantages be achieved?", Thromb Haemost, 103, pp.34~39 (2010)
- Amadeus Investigators., "Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation : a randomised, open-label, noninferiority trial", Lancet, 371, pp.315~321 (2008)
- Albers GW., "Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation : a randomized trial", JAMA, 293, pp.690~698 (2005)
- Gomez-Outes A., "Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons", BMJ, 344, pp.e3675~ (2012)
- Ntaios G., "Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack : a systematic review and meta-analysis of randomized controlled trials", Stroke, 43, pp.3298~3304 (2012)
- Eckman MH., "Moving the tipping point : the decision to anticoagulate patients with atrial fibrillation", Circ Cardiovasc Qual Outcomes, 4, pp.14~21 (2011)
- Furie KL., "Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation : a science advisory for healthcare professionals from the American Heart Association", American Stroke Association, 2012, pp.43, 3442~3453
- Ruff CT., "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
- Thrift AG., "Incidence of the major stroke subtypes : initial findings from the North East Melbourne Stroke Incidence Study(NEMESIS)", Stroke, 32, pp.1732~1738 (2001)
- Klatsky AL., "Risk of hemorrhagic stroke in Asian American ethnic groups", Neuroepidemiology, 25, pp.26~31 (2005)
- Ayala C., "Sex differences in US mortality rates for stroke and stroke subtypes by race", ethnicity and age, 1995-1998, 2002, pp.33, 1197~1201
- Koennecke HC., "Cerebral microbleeds on MRI : prevalence, associations, and potential clinical implications", Neurology, 66, pp.165~171 (2006)
- Lee SH., "Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging : analysis of risk factors for multifocal signal loss lesions", Stroke, 33, pp.2845~2849 (2002)
- Strazzullo P., "Salt intake, stroke, and cardiovascular disease : meta-analysis of prospective studies", BMJ, 339, pp.b4567~ (2009)
- Wong KS., "Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages", Neurology, 60, pp.511~513 (2003)
- Charidimou A., "Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk", Front Neurol, 3, pp.133~ (2012)
- Smith EE., "Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke", Neurology, 59, pp.193~197 (2002)
- Shen AY., "Racial", ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation, 2007, pp.50, 309~315
- 최스미, "뇌졸중 환자의 퇴원 후 한방 이용 실태 및 관련 요인", 대한뇌졸중학회지, 5(1), pp.64~69 (2003), 대한뇌졸중학회
- Kelner M., "Health care and consumer choice : medical and alternative therapies", Soc Sci Med, 45, pp.203~212 (1997)
- Wong RS., "Use of herbal medicines by patients receiving warfarin", Drug Saf, 26, pp.585~588 (2003)
- Wallentin L., "Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation : an analysis of the RE-LY trial", Lancet, 376, pp.975~983 (2010)
- Hori M., "Dabigatran versus warfarin : effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation", Stroke, 44, pp.1891~1896 (2013)
- JCS Joint Working Group., "Guidelines for pharmacotherapy of atrial fibrillation(JCS 2008) : digest version", Circ J, 74, pp.2479~2500 (2010)
- Takahashi H., "Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients", Clin Pharmacol Ther, 73, pp.253~263 (2003)
- Rieder MJ., "Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose", N Engl J Med, 352, pp.2285~2293 (2005)
- Takahashi H., "Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population dif-ferences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans", Pharmacogenet Genomics, 16, pp.101~110 (2006)
- Hori M., "Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study", Cir J, 76, pp.2104~2111 (2012)
- Ogawa S., "Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. – the ARISTOTLE-J study", Circ J, 75, pp.1852~1859 (2011)
- Chiang CE., "Stroke prevention in atrial fibrillation : an Asian perspective", Thromb Haemost, 111, pp.789~797 (2014)
- Kamel H., "Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack", Stroke, 43, pp.881~883 (2012)
- Kamel H., "Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation", Neurology, 79, pp.1428~1434 (2012)
- Harrington AR., "Costeffectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation", Stroke, 44, pp.1676~1681 (2013)
- Oh S., "The determinants of stroke phenotypes were different from the predictors(CHADS2 and CHA2DS2-VASc)of stroke in patients with atrial fibrillation : a comprehensive approach", BMC Neurol, 11, pp.107~ (2011)
- Ay H., "Admission international normalized ratio and acute infarct volume in ischemic stroke", Ann Neurol, 64, pp.499~506 (2008)
- Schulman S., "Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial", Ann Intern Med, 155, pp.W201~W203 (2011)
- Apostolakis S., "Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin : the SAMe-TT2R2 score", Chest, 144, pp.1555~1563 (2013)
- Boriani G., "Predicting the quality of anticoagulation during warfarin therapy : the basis for an individualized approach", Chest, 144, pp.1437~1438 (2013)